Kamada (KMDA) said Wednesday it opened a new plasma collection center in San Antonio, Texas, with an expected annual collection capacity of about 50,000 liters.
The plasma-derived protein therapeutics manufacturer said the new facility will collect normal source plasma for third-party sales and specialty plasma, including Anti-Rabies and Anti-D, for internal use.
The company said it expects sales of normal source plasma from the site to generate $8 million to $10 million annually at full capacity.
Kamada said it plans to seek regulatory approvals for the new site from the US Food and Drug Administration and the European Medicines Agency in H2.
Price: 6.69, Change: +0.03, Percent Change: +0.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.